Status quo to win out?, page-4

What follows is the the summary from the latest Bell Potter report. Target price reduced to $0.95 from $1. And perhaps damning with faint praise. No mention of DEP-Gemcetabine!

Starpharma (SPL): Q1FY23 Activity report and updates

SPL remains in a good financial position with a cash balance of $42.3 million as at 30 September 2022 and the company is expecting an additional $7m from the Government’s R&D tax incentive in the next few months.

SPL announced this quarter that it signed a second DEP® Research Agreement with MSD, meaning there are now two active antibody dendrimer conjugate (ADC) programs with MSD.

SPL has continued progress on other partnered DEP® programs, including with AstraZeneca, Genentech, and Chase Sun. AstraZeneca continued recruitment into two clinical trials of their DEP® nanoparticle formulation, AZD0466. The Phase 1/2 Advanced Haematological Malignancies trial continued to expand with 12 out of an expected 30+ sites now open. The Phase 1/2 Study of AZD0466 in Advanced Non- Hodgkin Lymphoma has also opened a number of sites in the US and Korea with ~20 sites planned globally.

SPL continues its three Phase 2 trials using its clinical-stage DEP® conjugated chemotherapy agents, DEP® cabazitaxel, DEP® docetaxel and DEP® irinotecan.